Publications by authors named "Korinna Kraft"
Article Synopsis
- Diabetic foot ulcers (DFUs) often resist standard treatments, leading to severe health risks; ABCB5 mesenchymal stem cells (MSCs) could serve as a promising new option due to their healing and anti-inflammatory properties.* -
- The study investigated the angiogenic capabilities of ABCB5 MSCs, showing that they can express factors necessary for blood vessel formation and enhance healing in animal models with ischemia.* -
- A clinical trial demonstrated the safety and effectiveness of applying ABCB5 MSCs to hard-to-treat DFUs, potentially offering a new treatment avenue for those suffering from chronic wounds.*
Article Synopsis
- Many chronic venous ulcers (CVUs) do not heal with standard care, but skin-derived ABCB5 mesenchymal stem cells (MSCs) show promise in improving healing by reducing inflammation.
- A phase I/IIa clinical trial tested these MSCs in patients resistant to typical treatment, where most adverse effects were mild and did not lead to long-term problems.
- The treatment led to a significant reduction in ulcer size after 12 weeks, indicating ABCB5 MSCs could be a valuable addition to therapies for tough-to-heal CVUs, warranting further larger studies.
Ex vivo-expanded highly pure ABCB5 mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data.
Andreas Kerstan Elke Niebergall-Roth Jasmina Esterlechner Hannes M Schröder Martin Gasser Korinna Kraft
Cytotherapy
February 2021
Article Synopsis
- Mesenchymal stromal cells (MSCs) are being explored for treating tissue damage, but their varying properties may explain inconsistent results in therapy; a specific MSC subset identified by the ABCB5 transporter has shown potential for improved outcomes.
- The researchers developed a compliant process to isolate and produce ABCB5 MSCs from skin, leading to a product approved for clinical trials aimed at treating chronic venous ulcers.
- Early results from treating nine patients show a significant median reduction in wound size (63%) after 12 weeks, suggesting that ABCB5 MSCs might provide an effective solution for challenging chronic wounds.
Article Synopsis
- - The study focuses on ABCB5-expressing mesenchymal stromal cells (MSCs) from human skin as a potential therapy for currently untreatable diseases, having developed a method to isolate and process these cells in line with international safety standards.
- - Extensive safety testing was conducted on ABCB5 MSCs, revealing no harmful effects such as abnormal cell growth, tumor formation, or adverse tissue reactions in animal models.
- - Results indicate that ABCB5 MSCs are safe and tolerable for local and systemic use, supporting their development as a new advanced-therapy medicinal product.
Background: Standardized and well-characterized genetic building blocks are a prerequisite for the convenient and reproducible assembly of novel genetic modules and devices. While numerous standardized parts exist for Escherichia coli, such tools are still missing for the Gram-positive model organism Bacillus subtilis. The goal of this study was to develop and thoroughly evaluate such a genetic toolbox.
View Article and Find Full Text PDF